Arcus Biosciences (RCUS) president sells 31K shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arcus Biosciences, Inc. president Juan C. Jaen, through a trust, sold a total of 31,431 shares of common stock of Arcus Biosciences in open-market transactions over June 22–24. The reported weighted average sale prices ranged from about $27.03 to $29.66 per share.

These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. After the most recent sale, the trust associated with Jaen held 890,809 shares indirectly, while a separate entry shows 378,291 shares held directly as of June 22. Footnotes note that the indirect holdings include unvested RSUs and 1,279 shares acquired through the company’s Employee Stock Purchase Plan.

Insights

Arcus president’s recent stock sales are modest relative to his remaining holdings and occur under a pre-set Rule 10b5-1 plan.

President Juan C. Jaen, via a trust, sold 31,431 shares of Arcus Biosciences common stock in open-market trades between June 22 and June 24, 2026. Reported weighted average prices ranged from about $27.03 to $29.66 per share, consistent with typical liquidity transactions rather than any derivative exercise.

The filing shows a substantial remaining equity position. After the latest sale, the trust still held 890,809 shares indirectly, and a separate direct holding line lists 378,291 shares as of June 22, 2026. The footnotes state the sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026, indicating the trades were pre-scheduled rather than opportunistic. The indirect position also includes unvested RSUs and 1,279 shares acquired through the Employee Stock Purchase Plan, underscoring continued alignment with shareholders despite the net-sell activity.

Insider Trade Summary 10b5-1

Net Seller: 31,431 shares ($877,501)

Net Sell 5 txns

Insider Jaen Juan C.

Role President

Sold 31,431 shs ($878K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,431	$29.6595	$191K
Sale	Common Stock	14,067	$27.6875	$389K
Sale	Common Stock	1,697	$28.0612	$48K
Sale	Common Stock	9,236	$27.0313	$250K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 890,809 shares (Indirect, By Trust); Common Stock — 378,291 shares (Direct, null)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes the unvested portion of the Reporting Person's RSU grants. Includes 1,279 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.

Key Figures

Total shares sold: 31,431 shares Sale price June 22: $27.0313 per share Sale price June 23 (block 1): $27.6875 per share +5 more

8 metrics

Total shares sold 31,431 shares Open-market sales on June 22–24, 2026

Sale price June 22 $27.0313 per share Weighted average price for 9,236 shares sold

Sale price June 23 (block 1) $27.6875 per share Weighted average price for 14,067 shares sold

Sale price June 23 (block 2) $28.0612 per share Weighted average price for 1,697 shares sold

Sale price June 24 $29.6595 per share Weighted average price for 6,431 shares sold

Indirect shares after trades 890,809 shares Indirectly held by trust after June 24, 2026 sale

Direct holdings 378,291 shares Directly held as of June 22, 2026

ESPP purchase 1,279 shares Purchased May 31, 2026 via Employee Stock Purchase Plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, Employee Stock Purchase Plan, RSU grants, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Purchase Plan financial

"Includes 1,279 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

RSU grants financial

"Includes the unvested portion of the Reporting Person's RSU grants."

indirect ownership financial

"direct_or_indirect": "I", "nature_of_ownership": "By Trust""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 05:42 PM Accepted by SEC EDGAR 06/24/2026 - 05:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaen Juan C.

(Last)

(First)

(Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD

CALIFORNIA

94545

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/22/2026		S⁽¹⁾		9,236	D	$27.0313⁽²⁾	913,004	I	By Trust
Common Stock	06/23/2026		S⁽¹⁾		14,067	D	$27.6875⁽³⁾	898,937	I	By Trust
Common Stock	06/23/2026		S⁽¹⁾		1,697	D	$28.0612⁽⁴⁾	897,240	I	By Trust
Common Stock	06/24/2026		S⁽¹⁾		6,431	D	$29.6595⁽⁵⁾	890,809	I	By Trust
Common Stock								378,291⁽⁶⁾⁽⁷⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

5. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

6. Includes the unvested portion of the Reporting Person's RSU grants.

7. Includes 1,279 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.

	/s/ Carolyn Tang, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Arcus Biosciences (RCUS) report for its president?

Arcus Biosciences reported that president Juan C. Jaen, through a trust, sold 31,431 shares of common stock in open-market transactions. The sales occurred on June 22–24, 2026, at weighted average prices between about $27.03 and $29.66 per share.

How many Arcus Biosciences (RCUS) shares did the president sell and at what prices?

Juan C. Jaen’s trust sold 31,431 Arcus Biosciences common shares. Reported weighted average sale prices were approximately $27.03, $27.69, $28.06, and $29.66 per share across the June 22–24, 2026 transactions, reflecting multiple open-market trades within those price ranges.

How many Arcus Biosciences (RCUS) shares does the president hold after these transactions?

After the latest transaction, the trust associated with president Juan C. Jaen held 890,809 Arcus Biosciences shares indirectly. A separate holding line shows 378,291 shares held directly as of June 22, 2026, indicating he retains a substantial ownership stake following the reported sales.

Were the Arcus Biosciences (RCUS) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Juan C. Jaen on February 27, 2026. Such plans pre-schedule trades, indicating the timing of these June 22–24, 2026 sales was determined in advance rather than on short notice.

What does ‘indirect ownership by trust’ mean in the Arcus Biosciences (RCUS) Form 4?

‘Indirect ownership by trust’ indicates the reported Arcus Biosciences shares are held through a trust associated with the reporting person, not in their personal name. In this case, the sales and remaining 890,809 shares are attributed to a trust linked to president Juan C. Jaen.

Do the Arcus Biosciences (RCUS) insider holdings include RSUs and ESPP shares?

Yes. A footnote explains the reported holdings include the unvested portion of Juan C. Jaen’s restricted stock unit grants. Another footnote notes that 1,279 shares within the holdings were purchased on May 31, 2026 through Arcus Biosciences’ Employee Stock Purchase Plan.